The expanded agreement extends the existing collaboration between the companies established in November 2025, under which Karo Healthcare is responsible for marketing, distribution, and sales across 19 European markets with a combined population of approximately 500 million people.

Saphnelo (anifrolumab) has been approved in the US for self-administration as a once-weekly autoinjector, the Saphnelo Pen, for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.

CEPI and the Recipharm company Analysis Zero have announced a new seed collaboration to advance the use of Nuclear Magnetic Resonance (NMR) as a real-time Process Analytical Technology (PAT) for RNA vaccine manufacturing.

Gradientech has received a Notice of Allowance in the United States for its single-use microfluidic test, a key component of the CE marked QuickMIC system.

The purpose of the Karolinska Institutet Centre for AI Innovation is to serve as a support centre and skills hub.

Healthcare registry data can show early risk patterns for melanoma skin cancer, according to a study from the University of Gothenburg.

The company has submitted an application for approval (BLA) to the US Food and Drug Administration for its biosimilar candidate to LUCENTIS (ranibizumab).

Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.

The European Investment Bank (EIB) is lending EUR 20 million to BioLamina to expand its development of laminin technologies.

Through a donation, a new foundation has been formed called Familjen Landegrens stiftelse för medicinsk forskning (Landegren Family Foundation for Medical Research). The purpose of this foundation is to support Uppsala University’s medical research and medical innovation.

For a long time, restoring vision has been like a search for the holy grail for scientists. And for many patients, being diagnosed with a severe retinal disease has meant progressive, irreversible vision loss. However, the past decade has seen some  of the clearest evidence so far that vision loss can be partially restored, not just preserved.

Sweden’s first clinical research center dedicated to ophthalmology has been established at St. Erik Eye Hospital in the Stockholm Region, in collaboration with Karolinska Institutet.